FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212851543> ?p ?o ?g. }

• W4212851543 endingPage "1604" @default.
• W4212851543 startingPage "1595" @default.
• W4212851543 abstract "Background Ofatumumab is a humanized type 1 anti‐CD20 monoclonal antibody. Preclinical studies show improved complement‐mediated cytotoxicity (CMC) compared to rituximab in mantle cell lymphoma (MCL). This study evaluates the safety and efficacy of combining ofatumumab with HyperCVAD/MA (O‐HyperCVAD) in newly diagnosed MCL. Methods In this single‐arm phase 2 study, 37 patients were treated with the combination of O‐HyperCVAD for 4 or 6 cycles, followed by high dose chemotherapy and autologous stem cell transplant. Primary objectives were overall response rate (ORR) and complete response (CR) rate at the end of therapy. Secondary objectives included minimal residual disease (MRD) negativity, progression‐free survival (PFS), and overall survival (OS). Results Median age was 60 years; ORR was 86% and 73% achieved a CR by modified Cheson criteria. The MRD negativity rate was 78% after 2 cycles of therapy, increasing to 96% at the end of induction; median PFS and OS were 45.5 months and 56 months, respectively. Achieving a post‐induction CR by both imaging and flow cytometry was associated with improved PFS and OS. Early MRD negativity (post‐2 cycles) was also associated with an improved PFS but not OS. There were 3 deaths while on therapy, and grades 3 and 4 adverse events (AEs) were observed in 22% and 68% of the patients. Conclusion The addition of ofatumumab to HyperCVAD/HD‐MA led to high rates of MRD negativity by flow cytometry in patients with newly diagnosed MCL. Achieving a CR post‐induction by both imaging and flow cytometry is associated with improved overall survival." @default.
• W4212851543 created "2022-02-24" @default.
• W4212851543 creator A5001862108 @default.
• W4212851543 creator A5008341315 @default.
• W4212851543 creator A5013168114 @default.
• W4212851543 creator A5016042168 @default.
• W4212851543 creator A5017390861 @default.
• W4212851543 creator A5017589040 @default.
• W4212851543 creator A5019982069 @default.
• W4212851543 creator A5022239437 @default.
• W4212851543 creator A5035548614 @default.
• W4212851543 creator A5037127160 @default.
• W4212851543 creator A5037345000 @default.
• W4212851543 creator A5042047926 @default.
• W4212851543 creator A5042987775 @default.
• W4212851543 creator A5043287179 @default.
• W4212851543 creator A5050643493 @default.
• W4212851543 creator A5053887896 @default.
• W4212851543 creator A5063296413 @default.
• W4212851543 creator A5064004889 @default.
• W4212851543 creator A5065111461 @default.
• W4212851543 creator A5065404552 @default.
• W4212851543 creator A5066598802 @default.
• W4212851543 creator A5069146590 @default.
• W4212851543 creator A5083278460 @default.
• W4212851543 creator A5084501814 @default.
• W4212851543 creator A5085325467 @default.
• W4212851543 creator A5087273890 @default.
• W4212851543 date "2022-02-14" @default.
• W4212851543 modified "2023-10-14" @default.
• W4212851543 title "Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study" @default.
• W4212851543 cites W1549556227 @default.
• W4212851543 cites W1912693401 @default.
• W4212851543 cites W2001799739 @default.
• W4212851543 cites W2022401246 @default.
• W4212851543 cites W2065464657 @default.
• W4212851543 cites W2077558947 @default.
• W4212851543 cites W2093893201 @default.
• W4212851543 cites W2125684345 @default.
• W4212851543 cites W2130669641 @default.
• W4212851543 cites W2133201432 @default.
• W4212851543 cites W2148775041 @default.
• W4212851543 cites W2156235279 @default.
• W4212851543 cites W2167387655 @default.
• W4212851543 cites W2189740376 @default.
• W4212851543 cites W2190580159 @default.
• W4212851543 cites W2430862255 @default.
• W4212851543 cites W2518731208 @default.
• W4212851543 cites W2553521990 @default.
• W4212851543 cites W2608724752 @default.
• W4212851543 cites W2749289906 @default.
• W4212851543 cites W2760635695 @default.
• W4212851543 cites W2982239386 @default.
• W4212851543 cites W3036787109 @default.
• W4212851543 cites W3047074915 @default.
• W4212851543 cites W3087400259 @default.
• W4212851543 cites W3194293108 @default.
• W4212851543 doi "https://doi.org/10.1002/cncr.34106" @default.
• W4212851543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35157306" @default.
• W4212851543 hasPublicationYear "2022" @default.
• W4212851543 type Work @default.
• W4212851543 citedByCount "0" @default.
• W4212851543 crossrefType "journal-article" @default.
• W4212851543 hasAuthorship W4212851543A5001862108 @default.
• W4212851543 hasAuthorship W4212851543A5008341315 @default.
• W4212851543 hasAuthorship W4212851543A5013168114 @default.
• W4212851543 hasAuthorship W4212851543A5016042168 @default.
• W4212851543 hasAuthorship W4212851543A5017390861 @default.
• W4212851543 hasAuthorship W4212851543A5017589040 @default.
• W4212851543 hasAuthorship W4212851543A5019982069 @default.
• W4212851543 hasAuthorship W4212851543A5022239437 @default.
• W4212851543 hasAuthorship W4212851543A5035548614 @default.
• W4212851543 hasAuthorship W4212851543A5037127160 @default.
• W4212851543 hasAuthorship W4212851543A5037345000 @default.
• W4212851543 hasAuthorship W4212851543A5042047926 @default.
• W4212851543 hasAuthorship W4212851543A5042987775 @default.
• W4212851543 hasAuthorship W4212851543A5043287179 @default.
• W4212851543 hasAuthorship W4212851543A5050643493 @default.
• W4212851543 hasAuthorship W4212851543A5053887896 @default.
• W4212851543 hasAuthorship W4212851543A5063296413 @default.
• W4212851543 hasAuthorship W4212851543A5064004889 @default.
• W4212851543 hasAuthorship W4212851543A5065111461 @default.
• W4212851543 hasAuthorship W4212851543A5065404552 @default.
• W4212851543 hasAuthorship W4212851543A5066598802 @default.
• W4212851543 hasAuthorship W4212851543A5069146590 @default.
• W4212851543 hasAuthorship W4212851543A5083278460 @default.
• W4212851543 hasAuthorship W4212851543A5084501814 @default.
• W4212851543 hasAuthorship W4212851543A5085325467 @default.
• W4212851543 hasAuthorship W4212851543A5087273890 @default.
• W4212851543 hasBestOaLocation W42128515431 @default.
• W4212851543 hasConcept C126322002 @default.
• W4212851543 hasConcept C141071460 @default.
• W4212851543 hasConcept C143998085 @default.
• W4212851543 hasConcept C2777525834 @default.
• W4212851543 hasConcept C2778461978 @default.
• W4212851543 hasConcept C2778714382 @default.
• W4212851543 hasConcept C2779338263 @default.
• W4212851543 hasConcept C2779823535 @default.

• next